US7301021B2
(en)
|
1997-07-02 |
2007-11-27 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
US6080763A
(en)
*
|
1997-11-03 |
2000-06-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds and their use as anti-inflammatory agents
|
EP1473292A1
(en)
*
|
1997-11-03 |
2004-11-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as anti-inflammatory agents
|
EP1056725B1
(en)
*
|
1997-12-22 |
2006-06-07 |
Bayer Pharmaceuticals Corp. |
Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
|
WO1999032111A1
(en)
*
|
1997-12-22 |
1999-07-01 |
Bayer Corporation |
INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
|
DK1690853T3
(da)
*
|
1999-01-13 |
2010-06-07 |
Bayer Healthcare Llc |
Omega-carboxyaryl-substituerede diphenylurinstoffer til anvendelse som raf-kinaseinhibitorer
|
EP1140840B1
(en)
*
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
EP1158985B1
(en)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
UA73492C2
(en)
*
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
MXPA01008440A
(es)
|
1999-02-22 |
2002-04-24 |
Boehringer Ingelheim Pharma |
Derivados heterociclicos policiclos como agentes anti-inflamatorios..
|
ATE278674T1
(de)
|
1999-03-12 |
2004-10-15 |
Boehringer Ingelheim Pharma |
Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
|
WO2000055152A1
(en)
*
|
1999-03-12 |
2000-09-21 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as anti-inflammatory agents
|
ES2253233T3
(es)
|
1999-07-09 |
2006-06-01 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Procedimiento para sintesis de compuestos de urea heteroaril sustituidos.
|
MXPA02004879A
(es)
|
1999-11-16 |
2002-08-30 |
Boehringer Ingelheim Pharma |
Derivados de urea como agentes antiinflamatorios.
|
AU1781601A
(en)
|
1999-11-23 |
2001-06-04 |
Smithkline Beecham Corporation |
3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
US6608052B2
(en)
|
2000-02-16 |
2003-08-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as anti-inflammatory agents
|
TWI282334B
(en)
*
|
2000-03-22 |
2007-06-11 |
22 2001 00 00 0 |
A61p 17/00 200601 a i vhtw a61p 29/00 200601 a i vhtw a61p 35/00 200601 a i vhtw a61p 37/00 200601 a i vhtw
|
US6645990B2
(en)
|
2000-08-15 |
2003-11-11 |
Amgen Inc. |
Thiazolyl urea compounds and methods of uses
|
DE60134679D1
(de)
|
2000-10-20 |
2008-08-14 |
Eisai R&D Man Co Ltd |
Stickstoff enthaltende aromatische Heterozyklen
|
WO2002044156A2
(en)
|
2000-11-29 |
2002-06-06 |
Glaxo Group Limited |
Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
|
DE10109204A1
(de)
*
|
2001-02-26 |
2002-09-19 |
4Sc Ag |
Verbindungen zur Behandlung von Protozoen-Erkrankungen
|
EP1395548A1
(en)
|
2001-02-26 |
2004-03-10 |
4Sc Ag |
Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments
|
MXPA03010487A
(es)
|
2001-05-16 |
2004-03-09 |
Boehringer Ingelheim Pharma |
Derivados de diarilurea utiles como agentes antiinflamatorios.
|
EP1395561A1
(en)
|
2001-05-25 |
2004-03-10 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Carbamate and oxamide compounds as inhibitors of cytokine production
|
CA2446193C
(en)
|
2001-06-05 |
2011-11-01 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
1,4-disubstituted benzo-fused cycloalkyl urea compounds
|
EP1408950B1
(en)
|
2001-07-11 |
2007-04-25 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Methods of treating cytokine mediated diseases
|
US6825184B2
(en)
|
2001-10-18 |
2004-11-30 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
1,4-Disubstituted benzo-fused urea compounds
|
DE10203086A1
(de)
*
|
2002-01-28 |
2003-07-31 |
Bayer Ag |
5-Ring Heterozyklen
|
EP1478358B1
(en)
*
|
2002-02-11 |
2013-07-03 |
Bayer HealthCare LLC |
Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
|
AU2003209118A1
(en)
|
2002-02-11 |
2003-09-04 |
Bayer Pharmaceuticals Corporation |
Aryl ureas as kinase inhibitors
|
WO2003068223A1
(en)
*
|
2002-02-11 |
2003-08-21 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenesis inhibiting activity
|
JP4629978B2
(ja)
|
2002-02-25 |
2011-02-09 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン媒介疾患の治療に有用な1,4−二置換ベンゾ縮合シクロアルキル尿素化合物
|
WO2004004725A2
(en)
|
2002-07-09 |
2004-01-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
|
AU2003257991A1
(en)
|
2002-08-08 |
2004-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
|
CA2497240A1
(en)
|
2002-08-29 |
2004-03-11 |
Andrew Asher Protter |
Methods of promoting osteogenesis
|
US7144911B2
(en)
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
US7202257B2
(en)
|
2003-12-24 |
2007-04-10 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
MXPA05009104A
(es)
|
2003-02-28 |
2006-05-31 |
Bayer Pharmaceuticals Corp |
Derivados de urea biciclica novedosa utiles en el tratamiento del cancer y otros trastornos.
|
WO2004085433A2
(en)
*
|
2003-03-28 |
2004-10-07 |
Pharmacia & Upjohn Company Llc |
Positive allosteric modulators of the nicotinic acetylcholine receptor
|
GB0320244D0
(en)
*
|
2003-05-06 |
2003-10-01 |
Aventis Pharma Inc |
Pyrazoles as inhibitors of tumour necrosis factor
|
CA2526636C
(en)
|
2003-05-20 |
2012-10-02 |
Bayer Pharmaceuticals Corporation |
Diaryl ureas for diseases mediated by pdgfr
|
CL2004001834A1
(es)
|
2003-07-23 |
2005-06-03 |
Bayer Pharmaceuticals Corp |
Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
|
AU2004270733B2
(en)
|
2003-09-11 |
2011-05-19 |
Itherx Pharma, Inc. |
Cytokine inhibitors
|
US7244441B2
(en)
|
2003-09-25 |
2007-07-17 |
Scios, Inc. |
Stents and intra-luminal prostheses containing map kinase inhibitors
|
EP1683785B1
(en)
|
2003-11-11 |
2013-10-16 |
Eisai R&D Management Co., Ltd. |
Urea derivative and process for producing the same
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
MXPA06012394A
(es)
|
2004-04-30 |
2007-01-31 |
Bayer Pharmaceuticals Corp |
Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
ES2322175T3
(es)
|
2004-09-17 |
2009-06-17 |
EISAI R&D MANAGEMENT CO., LTD. |
Composicion medicinal con estabilidad mejorada y gelificacion reducida.
|
JP2008523072A
(ja)
|
2004-12-07 |
2008-07-03 |
ルーカス ファーマシューティカルズ, インコーポレイテッド |
タンパク質キナーゼの阻害剤
|
EP1828169A2
(en)
|
2004-12-07 |
2007-09-05 |
Locus Pharmaceuticals, Inc. |
Urea inhibitors of map kinases
|
WO2006068591A1
(en)
*
|
2004-12-20 |
2006-06-29 |
Astrazeneca Ab |
Novel pyrazole derivatives and their use as modulators of nicotinic acetylcholine receptors
|
AU2005321946B2
(en)
*
|
2004-12-23 |
2012-08-16 |
Deciphera Pharmaceuticals, Llc |
Enzyme modulators and treatments
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
EP1676574A3
(en)
|
2004-12-30 |
2006-07-26 |
Johnson & Johnson Vision Care, Inc. |
Methods for promoting survival of transplanted tissues and cells
|
GB0500435D0
(en)
*
|
2005-01-10 |
2005-02-16 |
Novartis Ag |
Organic compounds
|
UA93673C2
(ru)
|
2005-03-07 |
2011-03-10 |
Баер Шеринг Фарма Акциенгезельшафт |
Фармацевтическая композиция, которая содержит омега-карбоксиарилзамещенную дифенилмочевину, для лечения paka
|
DE102005015253A1
(de)
*
|
2005-04-04 |
2006-10-05 |
Merck Patent Gmbh |
Pyrazolderivate
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
DE102005037499A1
(de)
*
|
2005-08-09 |
2007-02-15 |
Merck Patent Gmbh |
Pyrazolderivate
|
JP2009513649A
(ja)
*
|
2005-10-28 |
2009-04-02 |
イーライ リリー アンド カンパニー |
キナーゼ阻害剤
|
PE20070795A1
(es)
|
2005-10-28 |
2007-08-24 |
Lilly Co Eli |
Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
|
US8580798B2
(en)
|
2005-12-21 |
2013-11-12 |
Bayer Intellectual Property Gmbh |
Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
|
WO2007136103A1
(ja)
|
2006-05-18 |
2007-11-29 |
Eisai R & D Management Co., Ltd. |
甲状腺癌に対する抗腫瘍剤
|
EP2094268A2
(en)
|
2006-05-26 |
2009-09-02 |
Bayer HealthCare, LLC |
Drug combinations with substituted diaryl ureas for the treatment of cancer
|
WO2008026748A1
(fr)
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Agent antitumoral pour cancer gastrique non différencié
|
WO2008079972A2
(en)
|
2006-12-20 |
2008-07-03 |
Bayer Healthcare Llc |
4-{4- [ ({3-tert-butyl-1- [3- (hydroxymethyl) phenyl] - 1h- pyrazol- 5 -yl } carbamoyl) -amin o] -3-chlorophenoxy} -n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer
|
KR101445892B1
(ko)
|
2007-01-29 |
2014-09-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암 치료용 조성물
|
US8653091B2
(en)
|
2007-04-02 |
2014-02-18 |
Evotec Ag |
Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof
|
WO2008131253A1
(en)
|
2007-04-20 |
2008-10-30 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
WO2009035949A2
(en)
*
|
2007-09-13 |
2009-03-19 |
Arete Therapeutics, Inc. |
Soluble epoxide hydrolase inhibitors
|
US8952035B2
(en)
|
2007-11-09 |
2015-02-10 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
MX2011003553A
(es)
|
2008-10-02 |
2011-05-25 |
Respivert Ltd |
Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38.
|
GB0818033D0
(en)
|
2008-10-02 |
2008-11-05 |
Respivert Ltd |
Novel compound
|
EP2370428B1
(en)
|
2008-12-11 |
2016-08-10 |
Respivert Limited |
P38 map kinase inhibitors
|
BRPI0922572A2
(pt)
|
2008-12-17 |
2019-09-24 |
Scripps Research Inst |
método para cultivar células pluripotentes, cultura de células de mamífero pluripotentes, meio de cultura de célula, célula animal pluripotente isolada, e, método para aumentar a pluripotência de uma célula de mamífero.
|
GB0905955D0
(en)
|
2009-04-06 |
2009-05-20 |
Respivert Ltd |
Novel compounds
|
JP5787976B2
(ja)
|
2010-04-08 |
2015-09-30 |
レスピバート・リミテツド |
P38mapキナーゼ阻害剤としてのピラゾリルウレア
|
BR112012032462A2
(pt)
|
2010-06-25 |
2016-11-08 |
Eisai R&D Man Co Ltd |
agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
|
WO2012012404A1
(en)
|
2010-07-19 |
2012-01-26 |
Bayer Healthcare Llc |
Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
US8962650B2
(en)
|
2011-04-18 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
NZ618795A
(en)
|
2011-05-13 |
2015-07-31 |
Array Biopharma Inc |
Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
|
EP3444363B1
(en)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
EP2578582A1
(en)
|
2011-10-03 |
2013-04-10 |
Respivert Limited |
1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
|
MY167798A
(en)
|
2011-10-03 |
2018-09-26 |
Respivert Ltd |
1-pyrazolyl-3- (4- ( (2 -anilinopyrimidin- 4 - yl) oxy) napththalen- 1 - yl) ureas as p38 map kinase inhibitors
|
JP2015503504A
(ja)
*
|
2011-12-23 |
2015-02-02 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
ヘテロアリールおよびその使用
|
EP3553169B1
(en)
|
2011-12-28 |
2021-11-03 |
Kyoto Prefectural Public University Corporation |
Normalization of culture of corneal endothelial cells
|
US20150104870A1
(en)
|
2012-04-27 |
2015-04-16 |
Keio University |
Neuronal differentiation promoter
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
GB201214750D0
(en)
|
2012-08-17 |
2012-10-03 |
Respivert Ltd |
Compounds
|
GB201215357D0
(en)
|
2012-08-29 |
2012-10-10 |
Respivert Ltd |
Compounds
|
WO2014078322A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078408A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
DK2922844T3
(en)
|
2012-11-13 |
2018-03-05 |
Array Biopharma Inc |
N-PYRROLIDINYL, N'-PYRAZOLYL-URINE, THIOURINE, GUANIDINE AND CYANOGUANIDE COMPOUNDS AS TRKA-KINASE INHIBITORS
|
LT2920166T
(lt)
|
2012-11-13 |
2016-12-12 |
Array Biopharma, Inc. |
Bicikliniai karbamido, tiokarbamido, guanidino ir cianoguanidino junginiai, tinkami naudoti skausmo gydymui
|
WO2014078325A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
US9546156B2
(en)
|
2012-11-13 |
2017-01-17 |
Array Biopharma Inc. |
N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
|
US9809578B2
(en)
|
2012-11-13 |
2017-11-07 |
Array Biopharma Inc. |
Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
|
WO2014078378A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
US9969694B2
(en)
|
2012-11-13 |
2018-05-15 |
Array Biopharma Inc. |
N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
US9790178B2
(en)
|
2012-11-13 |
2017-10-17 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
MX2015004979A
(es)
|
2012-12-21 |
2015-07-17 |
Eisai R&D Man Co Ltd |
Forma amorfa de derivado de quinolina y metodo para su produccion.
|
EP2970190A1
(en)
|
2013-03-14 |
2016-01-20 |
Respivert Limited |
Kinase inhibitors
|
ES2687968T3
(es)
|
2013-05-14 |
2018-10-30 |
Eisai R&D Management Co., Ltd. |
Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
|
US9750723B2
(en)
|
2013-10-31 |
2017-09-05 |
Ohio University |
Prevention and treatment of non-alcoholic fatty liver disease
|
EP3069732B1
(en)
|
2013-11-14 |
2023-07-12 |
The Doshisha |
Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
|
CN113264921B
(zh)
|
2014-02-14 |
2024-09-13 |
瑞斯比维特有限公司 |
作为激酶抑制剂的吡唑基-脲
|
LT3154959T
(lt)
|
2014-05-15 |
2019-09-25 |
Array Biopharma, Inc. |
1-((3s,4r)-4-(3-fluorfenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)karbamidas kaip trka kinazės inhibitorius
|
US20170202818A1
(en)
|
2014-07-18 |
2017-07-20 |
Ohio University |
Methods and compositions to modify gsk-3 activity
|
BR112017002827B1
(pt)
|
2014-08-28 |
2023-04-18 |
Eisai R&D Management Co., Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
MX2017010474A
(es)
|
2015-02-25 |
2017-11-28 |
Eisai R&D Man Co Ltd |
Metodo para suprimir el amargor de un derivado de quinoleina.
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
SG11201710198YA
(en)
|
2015-06-16 |
2018-01-30 |
Eisai R&D Man Co Ltd |
Anticancer agent
|
SG11202007198WA
(en)
|
2018-01-31 |
2020-08-28 |
Deciphera Pharmaceuticals Llc |
Combination therapy for the treatment of gastrointestinal stromal tumors
|
UA128288C2
(uk)
|
2018-03-08 |
2024-05-29 |
Інсайт Корпорейшн |
СПОЛУКИ АМІНОПІРАЗИНДІОЛУ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font>
|
WO2019191032A1
(en)
|
2018-03-26 |
2019-10-03 |
Clear Creek Bio, Inc. |
Compositions and methods for inhibiting dihydroorotate dehydrogenase
|
US11046658B2
(en)
|
2018-07-02 |
2021-06-29 |
Incyte Corporation |
Aminopyrazine derivatives as PI3K-γ inhibitors
|
WO2021030405A1
(en)
|
2019-08-12 |
2021-02-18 |
Deciphera Pharmaceuticals, Llc |
Ripretinib for treating gastrointestinal stromal tumors
|
BR112022002609A2
(pt)
|
2019-08-12 |
2022-08-09 |
Deciphera Pharmaceuticals Llc |
Métodos de tratamento de tumores estromais gastrointestinais
|
KR20220123058A
(ko)
|
2019-12-30 |
2022-09-05 |
데시페라 파마슈티칼스, 엘엘씨. |
1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물
|
DK4084778T3
(da)
|
2019-12-30 |
2023-12-11 |
Deciphera Pharmaceuticals Llc |
Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf
|
US20210315880A1
(en)
|
2020-03-20 |
2021-10-14 |
Clear Creek Bio, Inc. |
Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|